Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001829126-23-006098
Filing Date
2023-09-14
Accepted
2023-09-14 16:15:39
Documents
65
Period of Report
2023-07-31

Document Format Files

Seq Description Document Type Size
1 10-Q organicellregen_10q.htm   iXBRL 10-Q 1088078
2 EXHIBIT 31.1 organicellregen_ex31-1.htm EX-31.1 16195
3 EXHIBIT 31.2 organicellregen_ex31-2.htm EX-31.2 16410
4 EXHIBIT 32.1 organicellregen_ex32-1.htm EX-32.1 5449
5 EXHIBIT 32.2 organicellregen_ex32-2.htm EX-32.2 5589
  Complete submission text file 0001829126-23-006098.txt   5237948

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE ocel-20230731.xsd EX-101.SCH 53884
7 XBRL CALCULATION FILE ocel-20230731_cal.xml EX-101.CAL 54301
8 XBRL DEFINITION FILE ocel-20230731_def.xml EX-101.DEF 174784
9 XBRL LABEL FILE ocel-20230731_lab.xml EX-101.LAB 312552
10 XBRL PRESENTATION FILE ocel-20230731_pre.xml EX-101.PRE 263496
59 EXTRACTED XBRL INSTANCE DOCUMENT organicellregen_10q_htm.xml XML 698917
Mailing Address 3321 COLLEGE AVENUE SUITE 246 DAVIE FL 33314
Business Address 3321 COLLEGE AVENUE SUITE 246 DAVIE FL 33314 888-963-7881
Organicell Regenerative Medicine, Inc. (Filer) CIK: 0001557376 (see all company filings)

EIN.: 474180540 | State of Incorp.: NV | Fiscal Year End: 1031
Type: 10-Q | Act: 34 | File No.: 000-55008 | Film No.: 231255267
SIC: 2836 Biological Products, (No Diagnostic Substances)